Financial Data and Key Metrics Changes - Total company revenue increased by 13.4% compared to last year's third quarter, reaching a quarterly record [4][18] - Adjusted EBITDA increased by 15.2% year-over-year, resulting in a 26 basis point improvement in adjusted EBITDA margins [4][21] - Cash balance as of September 30, 2025, was $804.7 million, with a net debt to adjusted EBITDA ratio of approximately 1.0 [14][22] Business Line Data and Key Metrics Changes - Advanced Imaging revenue increased by 13.0% on an aggregate basis and 9.9% on a same-center basis compared to last year's third quarter [6][18] - MRI volume increased by 14.8%, CT volume by 9.4%, and PET/CT volume by 21.1% year-over-year [18] - Digital Health revenue increased by 51.6% from last year's third quarter, driven by contributions from iCAD [19] Market Data and Key Metrics Changes - The blended adoption rate for the EBCD DeepHealth AI-powered breast cancer screening program is above 45% nationally [9] - Medicare reimbursement is expected to increase by approximately $4 million to $5 million in 2026, breaking a trend of annual cuts [25][26] Company Strategy and Development Direction - The company plans to continue expanding its Digital Health segment and has successfully integrated iCAD's operations, achieving cost synergies ahead of schedule [10][23] - There is a focus on enhancing operational efficiency through AI and digital solutions, which are expected to improve margins and capacity [56][60] - The company is evaluating an attractive pipeline of acquisition opportunities in both core imaging services and digital health [14][82] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to grow through patient referrals and contracts with radiology practices, despite challenges in the labor market [4][55] - The company anticipates that the labor market challenges may be at an inflection point, with potential stabilization in staffing issues [58][60] - Management highlighted the importance of AI in transforming healthcare delivery and improving patient outcomes [80] Other Important Information - The company will host its inaugural Investor Day, showcasing its digital health solutions and future growth strategies [27][30] - The implementation of See-Mode's thyroid ultrasound technology has shown a 30% reduction in scan time, enhancing operational efficiency [11] Q&A Session Summary Question: Update on TechLive rollout and dynamic scheduling - The TechLive rollout is expected to be substantially complete by the end of the year, significantly reducing exam room closures and increasing MRI volume [34][35] - Dynamic scheduling utilizes AI to predict patient no-shows, allowing for overbooking and better utilization of exam slots [36] Question: Progress on EBCD coverage and capitated contracts - Discussions with commercial payers regarding EBCD coverage are ongoing, with positive momentum expected [40] - Capitated payers are recognizing the value of early detection and are increasing rates for the EBCD program [42] Question: Outlook for joint ventures and partnerships - The company is receiving more inquiries from health systems regarding radiology strategies, indicating robust interest in partnerships [50][51] Question: Exposure to Medicaid programs and labor costs - Medicaid fee-for-service business constitutes about 2.5% of total revenue, with minimal impact expected from changes in Medicaid programs [52] - Labor costs remain a challenge, but the company is implementing various strategies to stabilize staffing [55] Question: Future of DeepHealth and sales personnel - The company recognizes the need for more sales personnel to effectively market DeepHealth solutions, leveraging cross-selling opportunities [90] Question: EBITDA margins and cost side considerations - The company is focused on margin improvement, with expectations that digital health initiatives will drive future margin expansion [96]